Nature Communications (May 2024)

The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans

  • Francesco Maura,
  • David G. Coffey,
  • Caleb K. Stein,
  • Esteban Braggio,
  • Bachisio Ziccheddu,
  • Meaghen E. Sharik,
  • Megan T. Du,
  • Yuliza Tafoya Alvarado,
  • Chang-Xin Shi,
  • Yuan Xiao Zhu,
  • Erin W. Meermeier,
  • Gareth J. Morgan,
  • Ola Landgren,
  • P. Leif Bergsagel,
  • Marta Chesi

DOI
https://doi.org/10.1038/s41467-024-48091-w
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Multiple myeloma (MM) is a heterogeneous disease characterized by frequent MYC translocations. Sporadic MYC activation in the germinal center of genetically engineered Vk*MYC mice is sufficient to induce plasma cell tumors in which a variety of secondary mutations are spontaneously acquired and selected over time. Analysis of 119 Vk*MYC myeloma reveals recurrent copy number alterations, structural variations, chromothripsis, driver mutations, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide (APOBEC) mutational activity, and a progressive decrease in immunoglobulin transcription that inversely correlates with proliferation. Moreover, we identify frequent insertional mutagenesis by endogenous retro-elements as a murine specific mechanism to activate NF-kB and IL6 signaling pathways shared with human MM. Despite the increased genomic complexity associated with progression, advanced tumors remain dependent on MYC. In summary, here we credential the Vk*MYC mouse as a unique resource to explore MM genomic evolution and describe a fully annotated collection of diverse and immortalized murine MM tumors.